Monalizumab: inhibiting the novel immune checkpoint NKG2A

The implementation of immune checkpoint inhibitors to the oncology clinic signified a new era in cancer treatment. After the first indication of melanoma, an increasing list of additional cancer types are now treated with immune system targeting antibodies to PD-1, PD-L1 and CTLA-4, alleviating inhi...

Descripción completa

Detalles Bibliográficos
Autores principales: van Hall, Thorbald, André, Pascale, Horowitz, Amir, Ruan, Dan Fu, Borst, Linda, Zerbib, Robert, Narni-Mancinelli, Emilie, van der Burg, Sjoerd H., Vivier, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798508/
https://www.ncbi.nlm.nih.gov/pubmed/31623687
http://dx.doi.org/10.1186/s40425-019-0761-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6798508/
https://www.ncbi.nlm.nih.gov/pubmed/31623687
http://dx.doi.org/10.1186/s40425-019-0761-3

Ejemplares similares